Decode Age Secures $1.7 Million Pre-Series A Funding to Advance Longevity Science and Gut Microbiome Research
核心洞察
Bengaluru-based longevity science startup Decode Age (搜索) raised Rs 14.48 crore ($1.7 million) in pre-Series A funding led by Dr Krishna Prasad Chigurupati of Granules India.
The company has built one of India's most advanced whole genome gut microbiome analysis systems to provide insights into microbial diversity's influence on immunity, metabolism and ageing pathways.
Funding will expand biomarker discovery programmes, advance multi-omics research pipeline, and support development of research-driven supplements targeting age-related conditions.
Bengaluru-based longevity science startup Decode Age (搜索) has secured Rs 14.48 crore (approximately $1.7 million) in its pre-Series A funding round, led by Dr Krishna Prasad Chigurupati, chairman and managing director of Granules India. The investment represents a significant milestone for the company founded in 2021, which operates at the intersection of aging biology, biomarker research, and gut microbiome science.
Advanced Microbiome Analysis Platform
Decode Age (搜索) has established a comprehensive longevity research platform that spans multi-omics testing, biomarker discovery, and precision-based interventions. At the core of this ecosystem is one of India's most advanced whole genome gut microbiome analysis systems, which provides high-resolution insights into microbial diversity and its influence on immunity, metabolism, and aging pathways.
The company's laboratory workflows prioritize precision and reproducibility, supporting researchers, clinicians, and individuals seeking deeper biological understanding and practical tools for healthy aging. The platform covers genome-scale gut microbiome analysis, metagenomics, and biomarker research, designed to deliver data-driven insights into long-term health and aging.
Research-Driven Product Development
Using insights from its microbiome research, Decode Age (搜索) is developing a new generation of research-driven supplements and longevity solutions informed by aging biology and microbiome data. The company focuses on supporting healthy aging and biological pathways associated with age-related conditions such as cancer, dementia, and other chronic diseases, aligning with prevailing scientific evidence and regulatory standards.
The startup's research targets key hallmarks of aging, including cellular energy, metabolic balance, inflammatory pathways, and cognitive resilience. These areas represent critical intervention points for addressing aging-related biological processes and supporting long-term health outcomes.
Strategic Investment and Expansion Plans
The new capital will enable Decode Age (搜索) to expand its biomarker discovery programmes, advance its multi-omics and microbiome research pipeline, and enhance scientific and analytical infrastructure. The funding will also support formulation research and facilitate deeper collaboration across the longevity ecosystem.
"This investment marks an important step forward in our mission to bring scientific precision to the way people understand their biology," said Parth Amin, CEO and co-founder of Decode Age (搜索). "The support from Dr Chigurupati strengthens our ability to advance ageing and gut microbiome research, expand our biomarker programmes and build the scientific infrastructure that drives our work."
Industry Leadership and Global Expansion
Dr Krishna Prasad Chigurupati brings over forty years of experience in the pharmaceutical industry as a pioneer of innovation, scale, and manufacturing excellence. His investment reflects confidence in Decode Age (搜索)'s scientific vision and long-term impact potential.
"Decode Age (搜索) is advancing an area of science that will redefine how we think about health, disease and ageing," stated Dr Chigurupati. "Their capabilities in gut microbiome research and ageing biology are rigorous and forward-looking, offering individuals and clinicians biological insights that were previously inaccessible."
The company is expanding its scientific and product teams as it prepares to extend its longevity research beyond India. Decode Age (搜索) collaborates with academic and global research initiatives, including work linked to the Indian Institute of Science (IISc) and international longevity programmes, to generate microbiome and aging data aligned with global research standards.